Fyn, Syk, and PI3K/Akt antagonists thus may present potential new therapeutic strategies that target the oncogene LMP1 for treatment of EBV+ B cell lymphomas. This evidence concerns the gene FYN and B-cell non-Hodgkin lymphoma.